Daptomycin: rationale and role in the management of skin and soft tissue infections
Author:
Open Access
- 1 November 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (Supplement) , iii15-iii23
Abstract
The emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide tolerance in S. aureus has underlined the importance of the newer anti-MRSA agents, particularly in the management of complicated skin and soft tissue infections (cSSTIs). The novel cyclic lipopeptide antibiotic daptomycin shows marked in vitro cidality against MRSA compared with both vancomycin and linezolid. Although comparative studies in cSSTIs have demonstrated non-inferiority with vancomycin and semi-synthetic penicillins, data from both clinical trials and observational studies suggest in vivo cidality as evidenced by rapid resolution of clinical signs of local inflammation and reduced duration of therapy. Overall success in SSTI post-marketing studies is >90%, and >88% in MRSA-infected patients, with no difference in the outcome observed between those with complicated versus uncomplicated infections. When used at licensed doses (4–6 mg/kg), daptomycin is safe and effective in SSTIs with significant muscle toxicity occurring in only 0.4% to 2.5% of patients. Clinical failure in daptomycin-treated SSTIs is associated with severity of infection (creatinine clearance <30 mL/min, intensive care unit stay and sepsis syndrome). Higher dosing at 6 mg/kg (with increased dosing interval in renal failure) should be considered in such patients as well as those at risk of bacteraemia, osteomyelitis, diabetic foot infection and in situations where there is more rapid drug clearance, such as infections complicating intravenous drug use and thermal burns. Once-daily dosing allows ease of use in both hospital and outpatient settings and may facilitate early discharge or avoided admission in some patient groups with SSTIs. Clinical experience to date suggests potential economic advantages associated with earlier hospital discharge and shorter duration of therapy, although further detailed cost-effectiveness comparisons are required to validate these observations in different healthcare settings.Keywords
This publication has 53 references indexed in Scilit:
- Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus Clone USA300 in Men Who Have Sex with MenAnnals of Internal Medicine, 2008
- Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2007
- Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT)International Journal of Antimicrobial Agents, 2007
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentNew England Journal of Medicine, 2006
- Community-acquired methicillin-resistant Staphylococcus aureus infectionsInternational Journal of Antimicrobial Agents, 2006
- Methicillin-ResistantStaphylococcus aureusDisease in Three CommunitiesNew England Journal of Medicine, 2005
- Managing skin and soft tissue infections: expert panel recommendations on key decision pointsJournal of Antimicrobial Chemotherapy, 2003
- Prediction Model to Identify Patients WithStaphylococcus aureusBacteremia at Risk for Methicillin ResistanceInfection Control & Hospital Epidemiology, 2003
- Risk of Methicillin‐ResistantStaphylococcus aureusInfection after Previous Infection or ColonizationClinical Infectious Diseases, 2003
- The Impact of Surgical-Site Infections in the 1990s: Attributable Mortality, Excess Length of Hospitalization, And Extra CostsInfection Control & Hospital Epidemiology, 1999